Literature DB >> 17350361

A cost-minimization analysis of the angio-seal vascular closure device following percutaneous coronary intervention.

Frederic S Resnic1, Nipun Arora, Michael Matheny, Matthew R Reynolds.   

Abstract

The Angio-Seal vascular closure device has been shown to be safe and effective in decreasing the time to hemostasis after percutaneous coronary intervention (PCI). The health economic implications of routinely using Angio-Seal after PCI have not been explored. We performed a cost-minimization analysis comparing routine Angio-Seal use after PCI with mechanical compression using a decision analytic model. The relative probabilities of 7 vascular access complications were derived from pooled analysis of published randomized trials. The incremental hospital cost of each vascular complication was estimated by a matched case-control analysis of 3,943 patients who underwent PCI at our center from January 2002 and December 2004. Appropriate sensitivity and uncertainty analyses were performed. After accounting for differences in expected rates of specific complications between the 2 strategies and the incremental costs of each vascular event, the routine use of Angio-Seal was associated with a lower cost per PCI procedure of 44 dollars. Probabilistic sensitivity analysis of all model assumptions using second-order Monte Carlo simulation confirmed the economic advantage of Angio-Seal in 74% of model replications. In conclusion, after PCI, the routine use of Angio-Seal for femoral vascular access management was associated with net cost savings compared with mechanical compression. This cost savings was in addition to the previously demonstrated advantages of Angio-Seal in terms of patient comfort and preference.

Entities:  

Mesh:

Year:  2007        PMID: 17350361      PMCID: PMC1864959          DOI: 10.1016/j.amjcard.2006.10.032

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

1.  Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade.

Authors:  F A Cura; S R Kapadia; P L L'Allier; J P Schneider; M S Kreindel; M J Silver; J S Yadav; C C Simpfendorfer; R R Raymond; E M Tuzcu; I Franco; P L Whitlow; E J Topol; S G Ellis
Journal:  Am J Cardiol       Date:  2000-10-01       Impact factor: 2.778

2.  Hospital resources consumed in treating complications associated with percutaneous coronary interventions.

Authors:  Aaron D Kugelmass; David J Cohen; Phillip P Brown; April W Simon; Edmund R Becker; Steven D Culler
Journal:  Am J Cardiol       Date:  2006-02-01       Impact factor: 2.778

3.  Propensity score analysis of vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention 1998-2003.

Authors:  Robert J Applegate; Matthew T Sacrinty; Michael A Kutcher; Talal T Baki; Sanjay K Gandhi; Renato M Santos; William C Little
Journal:  Catheter Cardiovasc Interv       Date:  2006-04       Impact factor: 2.692

4.  Femoral haemostasis after transcatheter therapeutic intervention: a prospective randomised study of the angio-seal device vs. the femostop device.

Authors:  F R Amin; M Yousufuddin; R Stables; W Shamim; F Al-Nasser; A J Coats; J Clague; U Sigwart
Journal:  Int J Cardiol       Date:  2000 Nov-Dec       Impact factor: 4.164

Review 5.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis.

Authors:  A Briggs; M Sculpher; M Buxton
Journal:  Health Econ       Date:  1994 Mar-Apr       Impact factor: 3.046

6.  Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices.

Authors:  G Dangas; R Mehran; S Kokolis; D Feldman; L F Satler; A D Pichard; K M Kent; A J Lansky; G W Stone; M B Leon
Journal:  J Am Coll Cardiol       Date:  2001-09       Impact factor: 24.094

7.  Vascular closure devices and the risk of vascular complications after percutaneous coronary intervention in patients receiving glycoprotein IIb-IIIa inhibitors.

Authors:  F S Resnic; G J Blake; L Ohno-Machado; A P Selwyn; J J Popma; C Rogers
Journal:  Am J Cardiol       Date:  2001-09-01       Impact factor: 2.778

8.  Vascular access site complications with the use of closure devices in patients treated with platelet glycoprotein IIb/IIIa inhibitors during rescue angioplasty.

Authors:  Fernando Boccalandro; Abid Assali; Kenichi Fujise; Richard W Smalling; Stefano Sdringola
Journal:  Catheter Cardiovasc Interv       Date:  2004-11       Impact factor: 2.692

9.  Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients.

Authors:  E F Halpern; M C Weinstein; M G Hunink; G S Gazelle
Journal:  Med Decis Making       Date:  2000 Jul-Sep       Impact factor: 2.583

10.  Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.

Authors:  David J Cohen; A Michael Lincoff; Tara A Lavelle; Huei-Ling Chen; Ameet Bakhai; Ronna H Berezin; Daniel Jackman; Ian J Sarembock; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

View more
  15 in total

Review 1.  Echocardiographic guidance for diagnostic and therapeutic percutaneous procedures.

Authors:  Cam Tu Nguyen; Eunice Lee; Huai Luo; Robert J Siegel
Journal:  Cardiovasc Diagn Ther       Date:  2011-12

Review 2.  Achieving safe femoral arterial access.

Authors:  Michael S Lee; Jeremy Kong
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

Review 3.  Vascular access and closure in coronary angiography and percutaneous intervention.

Authors:  Robert A Byrne; Salvatore Cassese; Maryam Linhardt; Adnan Kastrati
Journal:  Nat Rev Cardiol       Date:  2012-11-27       Impact factor: 32.419

4.  Bleeding avoidance strategies. Consensus and controversy.

Authors:  Harold L Dauerman; Sunil V Rao; Frederic S Resnic; Robert J Applegate
Journal:  J Am Coll Cardiol       Date:  2011-06-28       Impact factor: 24.094

5.  Delayed complication from a percutaneous vascular closure device following a neuro-interventional procedure.

Authors:  Ahmed Khaldi; B Waldau; C Skowlund; G J Velat; J Mocco; B L Hoh
Journal:  Interv Neuroradiol       Date:  2011-12-16       Impact factor: 1.610

6.  Incidence of delayed angiographic femoral artery complications using the EXOSEAL vascular closure device.

Authors:  Ramesh Grandhi; Xiaoran Zhang; David Panczykowski; Phillip Choi; Christopher T Hunnicutt; Ashutosh P Jadhav; Andrew F Ducruet; Tudor Jovin; Brian Jankowitz
Journal:  Interv Neuroradiol       Date:  2015-05-26       Impact factor: 1.610

7.  Vascular closure device failure in contemporary practice.

Authors:  Venkatesan D Vidi; Michael E Matheny; Usha S Govindarajulu; Sharon-Lise T Normand; Susan L Robbins; Vikram V Agarwal; Sripal Bangalore; Frederic S Resnic
Journal:  JACC Cardiovasc Interv       Date:  2012-08       Impact factor: 11.195

8.  Routine femoral head fluoroscopy to reduce complications in coronary catheterization.

Authors:  Joshua A Jacobi; Jeffrey M Schussler; Kenneth B Johnson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-01

9.  Quantitative impact of cardiovascular risk factors and vascular closure devices on the femoral artery after repeat cardiac catheterization.

Authors:  Klaus A Tiroch; Michael E Matheny; Frederic S Resnic
Journal:  Am Heart J       Date:  2010-01       Impact factor: 4.749

10.  Vascular closure device failure: frequency and implications: a propensity-matched analysis.

Authors:  Sripal Bangalore; Nipun Arora; Frederic S Resnic
Journal:  Circ Cardiovasc Interv       Date:  2009-10-27       Impact factor: 6.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.